Jaguar Health — Third Quarter 2026 Earnings Summary
Financial Performance:
- Total net revenue was $2.343 million for the three months ended September 30, 2026, a 24.0% decrease from $3.083 million in the same period in 2025.
- License and grant revenue, net, increased to $1.792 million in Q3 2026 from $42,000 in Q3 2025, representing a 4,166.7% increase.
- Product revenue, net, decreased to $551,000 in Q3 2026 from $3.041 million in Q3 2025, a decline of 81.9%.
- Loss from operations was $6.023 million in Q3 2026, an improvement of $1.215 million (16.8%) compared to a loss of $7.238 million in Q3 2025.
- Net loss was $5.830 million in Q3 2026, a 39.6% improvement from a net loss of $9.648 million in Q3 2025.
- Net loss per share, basic and diluted, was $(9.23) in Q3 2026 compared to $(2,032.95) in Q3 2025.
- Non-GAAP Recurring EBITDA was a net loss of approximately $5.0 million in Q3 2026, compared to a net loss of approximately $9.0 million in Q3 2025.
- Non-GAAP EBITDA was a net loss of $5.590 million in Q3 2026, compared to a net loss of $9.025 million in Q3 2025.
- Cost of product revenue increased to approximately $0.6 million in Q3 2026 from $0.5 million in Q3 2025.
- Research and development expenses decreased to $3.6 million in Q3 2026 from $3.7 million in Q3 2025.
- Sales and marketing expenses decreased to approximately $51,000 in Q3 2026 from $2.0 million in Q3 2025.
- General and administrative expenses decreased to $4.0 million in Q3 2026 from $4.1 million in Q3 2025.
- Interest expense was $156,000 in Q3 2026, compared to interest income of $6,000 in Q3 2025.
- The Company recognized a gain on extinguishment of debt of $0.6 million in Q3 2026, compared to $0 in Q3 2025.
- The fair value of financial and hybrid instruments designated at Fair Value Option decreased by a loss of $96,000 in Q3 2026, compared to a loss of $2.3 million in Q3 2025.
- Deferred revenue associated with a European partner contract totaled $425,000 as of September 30, 2026.
Guidance and Future Outlook:
- The Company expects to continue providing clinical milestones for its rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome.
- Jaguar plans to file a New Drug Application (NDA) for crofelemer powder for oral solution for MVID in mid-2027.
Business Segments and Product Lines:
- Effective January 12, 2026, Jaguar entered a U.S. commercial licensing agreement with Woodward Specialty, LLC, an affiliate of Future Pak, making Future Pak the exclusive U.S. marketer for Mytesi® and Canalevia®-CA1.
- Jaguar operates as a distribution entity for Mytesi and Canalevia-CA1, supplying products to Future Pak at cost-plus terms.
- License revenues recognized in Q1 2026 included a $16 million upfront payment and a $3 million payment for early termination of the Buy-Back Option.
- Jaguar satisfied closing conditions in August 2026 to receive the non-dilutive approximately $1.8 million holdback amount of the upfront fee from Future Pak.
- License fees of $42,000 were recognized in Q3 2026 from a securities purchase agreement with a European partner, consistent with $42,000 recognized in each quarter of 2025.
- No Federal grant revenue was recognized in Q3 2026 for the clinical study related to chemotherapy-induced diarrhea (CID) in dogs; $25,000 was recognized for the nine months ended September 30, 2026.
- Neonorm® non-prescription product revenues were consistent and minimal for Q3 2026 and Q3 2025.
- The Company dissolved the Jaguar/Napo Sales and Marketing Group as of January 12, 2026.
Market and Competitive Landscape:
- The Company's strategic focus has shifted to advancing the development of crofelemer for rare-disease indications related to intestinal failure in humans.
- Future Pak is a privately held company and does not report Mytesi sales.
Risks and Challenges:
- The press release notes that forward-looking statements are subject to risks, uncertainties, and assumptions that cannot be predicted or quantified and are beyond the Company's control.
- Specific risks include the timing of the NDA filing and the success of clinical milestones.
Management Commentary and Tone:
- Management highlighted the strategic alignment of the licensing agreement with Future Pak to focus resources on late-stage development programs.
- The reduction in operating expenses was attributed to the Future Pak licensing agreement and the dissolution of the sales and marketing group.
- The Company significantly reduced its outstanding debt balance by $10.1 million in Q3 2026.
Other Key Points:
- Jaguar exchanged shares of its common stock with Streeterville to fully repay and cancel the Streeterville New Note, resulting in a gain on extinguishment of debt.
- The Company will host an investor webcast on Tuesday, November 17, 2026, at 8:30 a.m. Eastern regarding Q3 2026 financials and company updates.
- Crofelemer is the only oral FDA-approved prescription drug under botanical guidance, extracted from the red bark sap of the Croton lechleri tree.
- Napo Pharmaceuticals has established a sustainable harvesting program for crofelemer under fair trade practices.
- Magdalena Biosciences, a joint venture between Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications.
- Company
- JAGUAR HEALTH INC
- Sector
- Healthcare
- Industry
- Biotechnology